Investigational Drug Information for PSN-375,963
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug PSN-375,963?
PSN-375,963 is an investigational drug.
There have been 7 clinical trials for PSN-375,963.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Back Pain. The leading clinical trial sponsors are Sanofi, University of Alberta, and University of Toronto.
There are seventeen US patents protecting this investigational drug and one hundred and eighty-one international patents.
Summary for PSN-375,963
| US Patents | 17 |
| International Patents | 181 |
| US Patent Applications | 42 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 3 (2020-07-01) |
| Vendors | 19 |
Recent Clinical Trials for PSN-375,963
| Title | Sponsor | Phase |
|---|---|---|
| Topical Vancomycin Over Sternal Edge in Cardiac Surgery | National Cheng-Kung University Hospital | Phase 4 |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Alberta | N/A |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Toronto | N/A |
Clinical Trial Summary for PSN-375,963
Top disease conditions for PSN-375,963
Top clinical trial sponsors for PSN-375,963
US Patents for PSN-375,963
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PSN-375,963 | See Plans and Pricing | Modulators of sphingosine phosphate receptors | The Scripps Research Institute (La Jolla, CA) | See Plans and Pricing |
| PSN-375,963 | See Plans and Pricing | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (San Diego, CA) | See Plans and Pricing |
| PSN-375,963 | See Plans and Pricing | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (San Diego, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PSN-375,963
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PSN-375,963 | Australia | AU2009258242 | 2028-05-14 | See Plans and Pricing |
| PSN-375,963 | Australia | AU2015213309 | 2028-05-14 | See Plans and Pricing |
| PSN-375,963 | Brazil | BRPI0912545 | 2028-05-14 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
